Managing Skeletal-Related Events in Breast Cancer, Part I
Panelists: William J. Gradishar, MD, Northwestern;Joyce O’Shaughnessy, MD, Texas Oncology; Christy A. Russell, MD, USC Norris; Debu Tripathy, MD, USC Norris; Linda Vahdat, MD, Weill Cornell Medical College
Published Online: Monday, December 3, 2012
For High-Definition, Click
Skeletal-related events (SREs) are common when administering both hormonal therapy and chemotherapy for patients with breast cancer. In recent years, several new treatment options have been approved that significantly help reduce SREs and improve quality of life.
Joyce A. O’Shaughnessy, MD, discusses results from clinical trials that compared the RANK ligand inhibitor denosumab to zoledronic acid in several tumor types. Overall, in metastatic breast cancer, denosumab showed superiority at reducing the occurrence of SREs. O'Shaughnessy explains that both these treatments are reasonable options but that she prefers denosumab for patients with newly diagnosed bone metastases or those progressing on IV bisphosphonates.
Christy A. Russell, MD, notes that a shortcoming of these trials is a lack of long-term data. Additionally, she feels the dosing schedule can be improved upon further. Moderator, Debu Tripathy, MD, believes that translating these agents into the early stage setting is one of the biggest challenges facing researchers.
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.